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Background. Risk assessment is the cornerstone of primary
prevention of cardiovascular disease. Our objective was to eval-
uate the prognostic value of the Framingham score in microal-
buminuric subjects without a history of cardiovascular disease
and whether this risk score can predict the benefit of treatment
with fosinopril or pravastatin.
Methods. Subjects were randomized to fosinopril 20 mg or
matching placebo, and to pravastatin 40 mg or matching placebo
(mean age 51 ± 12 years, 65% men, N = 830). Prediction of
10-year risk for coronary heart disease by the Framingham score
was performed using the risk factor categories with LDL choles-
terol.
Results. Albuminuria was correlated with Framingham score
at baseline (P < 0.001). In the population with a Framingham
risk score <20%, both albuminuria and Framingham risk score
were independent predictors of the primary end point. A two-
fold increase of albuminuria or the Framingham risk score was
associated with a hazard ratio of 1.60 (95% CI 1.10–2.31), P =
0.013 and 3.00 (95% CI 1.40–6.44), P = 0.005, respectively. In
contrast to fosinopril, pravastatin showed a significant benefi-
cial effect on Framingham risk score after 4 years of follow-up
(P < 0.001). Furthermore, the observed absolute risk reduc-
tion in cardiovascular events was greater than calculated by the
Framingham risk score.
Conclusion. The Framingham score is useful in microalbu-
minuric subjects as a prognostic tool. In addition, when con-
sidering the risk score as a target of intervention, the benefi-
cial effects of therapies might be underestimated. Combining
the Framingham score with the level of urinary albumin excre-
tion is suggested as a primary prevention strategy with higher
efficiency.
It has been generally accepted that early detection of
cardiovascular risk and subsequent intervention can pre-
vent coronary heart disease (CHD). The traditional car-
diovascular risk factors are male gender, age, cigarette
smoking, elevated blood pressure, high LDL cholesterol,
low HDL cholesterol, and diabetes. All these cardiovas-
cular risk factors are included in the Framingham car-
diovascular risk score. This score can help physicians to
predict 10-year risk for major cardiovascular events in
Key words: microalbuminuria, Framingham score, primary prevention.
C© 2004 by the International Society of Nephrology
the individual patient. Studies also show that the higher
the risk for developing CHD, the higher the efficacy of
the intervention is. However, several primary prevention
trials have demonstrated a significant effect of interven-
tion on cardiovascular events in patients with a lower
risk score [1, 2]. Limited data are available on the recom-
mended strategy in lower risk populations with a 10-year
risk between 10% to 20%. New tools such as noninvasive
imaging and novel serum markers are in development to
use in clinical practice. These markers may be used after
assessment of traditional cardiovascular risk factors to
identify the persons whom need aggressive intervention
despite their moderate risk. A new relatively inexpensive
to be measured risk indicator is microalbuminuria, which
has been associated with an increased risk for cardiovas-
cular disease in subjects with hypertension and diabetes,
but also in the general population [3]. The Prevention
of REnal and Vascular ENdstage Disease Intervention
Trial demonstrated that treatment with fosinopril had a
significant effect on urinary albumin excretion, and was
associated with a trend in reducing cardiovascular events.
Treatment with pravastatin did not result in a significant
reduction in urinary albumin excretion or a reduction
in the primary end point [4]. All these subjects had no
indication for primary prevention at inclusion. In this
supplementary-analysis of the PREVEND IT, we eval-
uated the prognostic value of the Framingham risk score
in microalbuminuric subjects without a history of cardio-
vascular disease and whether this risk score can predict
the benefit of treatment with fosinopril or pravastatin.
METHODS
The PREVEND IT was an investigator-initiated,
single-center, double-blind, randomized, placebo-
controlled trial with a 2 × 2 factorial design. Subjects
were randomized to fosinopril 20 mg or matching
placebo, and to pravastatin 40 mg or matching placebo
(N = 864). The key entry criteria were persistent mi-
croalbuminuria (once a urinary albumin concentration
>10 mg/L in an early morning spot urine, and at least
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Table 1. Baseline characteristics
Framingham risk score
<10% 10% to 20% >20% Total
Age years 43 ± 9 52 ± 9 62 ± 9 51 ± 12
Male gender 44.6% 74.1% 88.7% 64.9%
Systolic blood pressure mm Hg 122 ± 14 131 ± 16 141 ± 17 130 ± 18
Diastolic blood pressure mm Hg 71 ± 8 78 ± 9 82 ± 9 76 ± 10
LDL-cholesterol mmol/L 3.7 ± 0.8 4.2 ± 0.9 4.5 ± 1.0 4.1 ± 1.0
HDL-cholesterol mmol/L 1.1 ± 0.3 1.0 ± 0.3 0.9 ± 0.2 1.0 ± 0.3
Current smoking 29.8% 48.2% 47.4% 39.8%
Diabetes 0.3% 3.1% 5.7% 2.5%
Albuminuria mg/24h 19.6 (13.9–36.8) 22.9 (16.0–38.9) 28.6 (18.2–50.6) 22.6 (15.6–40.8)
Framingham risk score % 5.2 (3.0–7.2) 13.8 (11.6–16.8) 29.9 (24.3–39.5) 11.1 (5.6–21.2)
Data are given as mean ± standard deviation, except for albuminuria and Framingham risk score, which are presented as median (interquartile range).
once 15 to 300 mg/24 hours in 2 × 24-hour urine samples),
blood pressure <160/100 mm Hg without the use of
antihypertensive medication, and total cholesterol <8.0
mmol/L or <5.0 mmol/L in case of previous myocardial
infarction, and without the use of lipid-lowering drugs.
The laboratory and diagnostic methods to measure risk
factors and the definition of the primary end point are
described previously [5]. Prediction of CHD risk by
the Framingham risk score was performed using the
risk factor categories with LDL cholesterol reported by
Wilson et al [6]. The scores provide estimates of CHD
risk during a period of 10-year based on the Framingham
study in men and women aged 30 to 74. To evaluate the
Framingham risk score in our population, we excluded
subjects with a history of cardiovascular disease. From
the 864 subjects, 34 subjects were excluded, 29 because
of a history of cardiovascular disease, and 5 subjects due
to missing LDL-cholesterol values at baseline. Finally,
830 subjects were eligible to analyze the prognostic
value of the Framingham risk score at baseline. The
effect of intervention on reduction in Framingham
risk score was evaluated by comparing three months’
treatment data with baseline scores. Nonparametric
Mann-Whitney tests were used to test the difference
in Framingham risk score between placebo and active
treatment after four years of follow-up. Cox regression
analysis was used to investigate the prognostic value of
albuminuria and Framingham risk score. Albuminuria
and the Framingham risk score showed a log-linear
functional form with the response variable, and were
subsequently transformed to a two-log scale. Using
this transformation, the relative risk estimates should
be interpreted as if values of albuminuria or Fram-
ingham risk score were doubled (e.g., 20 mg/24h vs.
10 mg/24h, or 10% vs. 5%). All calculations were
performed with SPSS version 11.0.1 software (SPSS,
Chicago, IL, USA). The study was approved by the
Institutional Review Board, and conducted in accor-
dance with the guidelines of the Declaration of Helsinki.
Informed consent was obtained from all subjects before
randomization.
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Fig. 1. Kaplan-Meier analysis illustrating the prognostic value of Fram-
ingham risk score in microalbuminuric subjects. The population is di-
vided in three groups according to 10-year risk on cardiovascular dis-
ease. Hazard ratios (95% CIs) are given for the groups with a score
between 10% to 20% and >20%.
RESULTS
The baseline characteristics for the total population
and the three Framingham risk strata are summarized
in Table 1. Almost half of our population (44.8%) has
a Framingham risk score <10%, 27.5% has a risk score
between 10% to 20%, and 27.7% has a risk score >20%.
The level of albuminuria itself was significantly corre-
lated with the Framingham score at baseline (P for linear
trend <0.001). As illustrated in Figure 1, the Framing-
ham risk score has prognostic value in microalbuminuric
subjects. In the population with a Framingham risk score
<20%, albuminuria and Framingham risk score itself
were independent predictors of the primary end point.
A two-fold increase of albuminuria or Framingham risk
score was associated with a hazard ratio of 1.60 (95% CI
1.10–2.31), P = 0.013, and 3.00 (1.40–6.44), P = 0.005),
respectively.
In four years of follow-up, 41 primary end points oc-
curred, 1.3% of the subjects with a Framingham <10%
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Fig. 2. The effects of fosinopril and pravas-
tatin on the calculated Framingham risk score
and the observed incidence of cardiovascular
events during four years of follow-up.
had an end point, 5.3% in the group between 10% to 20%,
and 10.4% in the group with a Framingham >20%. These
incidences were comparable with the predicted incidence
of cardiovascular events over the four-year period: 2.1%,
5.5%, and 11.9%, respectively. As shown in Figure 2, fos-
inopril and pravastatin both decreased the event rate over
four years calculated by Framingham risk score by 1.1%
and 0.8%, respectively. Interestingly, the observed reduc-
tion during the four-year follow-up was greater than the
calculated reduction (3.1% and 1.3%, respectively).
Despite a significant reduction of fosinopril in cardio-
vascular events, no beneficial effect could be demon-
strated on Framingham risk score after four years of
follow-up. Median (interquartile range) delta Framing-
ham risk score was 6.01% in the fosinopril group ver-
sus 6.42% in the placebo group. In contrast to fosinopril,
pravastatin did show a positive and long-term effect on
Framingham risk score. In the pravastatin group a me-
dian (interquartile range) delta Framingham risk score
of 3.74% was observed in comparison to 8.53% in the
placebo group (P < 0.001).
DISCUSSION
In a microalbuminuric population, a strong prognostic
value of the Framingham risk score was observed. Mi-
croalbuminuria itself, as indicator of increased cardiovas-
cular risk, is correlated with this Framingham risk score,
and was an independent predictor of primary end points
in subjects with a Framingham risk score <20%. In con-
trast to fosinopril, pravastatin showed a significant ben-
eficial effect on Framingham risk score after four years’
follow-up (P < 0.001). Furthermore, the observed abso-
lute risk reduction in cardiovascular events was greater
than calculated by the Framingham risk score.
In our main report on the results of the PREVEND
IT study, we already observed that fosinopril, but not
pravastatin, had an effect on microalbuminuria. Many
studies have shown that the presence and magnitude of
risk factors is associated with the level of microalbumin-
uria. The fact that the calculated effect of pravastatin
on the risk score is lower than the calculated effect for
fosinopril is in line with the observed difference in their
effect on microalbuminuria. Furthermore, the predicted
difference in incidence of cardiovascular events between
the pravastatin and fosinopril group is in line with the
observed incidence. However, it is also evident that for
both groups the Framingham score is underestimating
the beneficial effect of treatment substantially. This sug-
gests that including microalbuminuria in the algorithm
for the Framingham score could improve the prediction
for those treatments, which have an effect on the level of
urinary albumin excretion. Especially microalbuminuria
could improve the predictive value of the Framingham
risk score in subjects with a risk score below 20%.
CONCLUSION
The Framingham risk score predicts also in microalbu-
minuric subjects the incidence of cardiovascular events.
However, the beneficial effects of therapies reducing
albumin excretion are underestimated. Combining the
Framingham score with the level of urinary albumin ex-
cretion is suggested as a primary prevention strategy with
high efficiency.
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